
Why Quality Rules Keep Plastic Products Top-Notch
Quality rules make sure plastic products are safe and work right. They keep customers happy and make brands look good. Bad quality can cause big problems, like broken stuff or health risks. For example, a bad food container could leak yucky stuff. Rules also help companies follow laws and sell all over the world. Here's why they're key:
Rules check that plastics don't have harmful stuff. This is huge for food and medical products, where safety can't be skipped.
Rules make sure every product is just as good as the last. This builds trust for a plastic product company. Good quality means happy customers and fewer returns.
Lots of countries want products to meet certain rules. Following these lets companies sell everywhere. For example, ISO rules are okay in over 160 countries, helping businesses grow.
Rules push for green practices, like recycling. This helps a plastic manufacturing company cut waste and look eco-friendly.
There are big rules that guide the plastic world. They cover materials, making stuff, and testing. Here's the top ones:
ISO 9001 is about keeping quality steady. It makes companies follow the same steps every time. For example, it checks raw materials before starting. Over 1 million companies use this rule.
This rule is for plastics used with food. It makes sure containers are safe for food and don't leak chemicals. PET and HDPE plastics usually pass this rule.
ASTM D6868 tests biodegradable plastics like polylactic acid (PLA). It checks if they break down safely in compost. This matters for eco-friendly packaging.
In the U.S., the FDA sets rules for plastics in food and medical stuff. It bans bad chemicals like BPA in some products. Plastics like PET and PP gotta pass FDA tests.
In Europe, REACH controls chemicals in plastics. It limits toxic stuff to keep people and nature safe. Companies gotta list what chemicals they use.
A plastic manufacturing company follows clear steps to meet these rules. Here's how it works:
Companies pick safe, strong materials. For example, PET is used for food bottles 'cause it's FDA-approved. Tests check if materials are tough and safe.
Factories use careful ways to shape plastics. Machines are set up to avoid mistakes. For example, making car parts needs super exact measurements, like within 0.01 mm.
Products get tested for strength and safety. Tests check for stress and chemicals. Outside labs, like SGS, say if products meet rules like ISO or FDA.
Regular checks make sure everything follows rules. ISO 9001 needs yearly reviews. This keeps a plastic product company doing things right.
Companies write down everything—where materials come from, test results, and how stuff's made. These records prove they follow rules when checked.
Meeting these rules brings big wins for businesses and customers. Here's how: Builds Trust : Good standards make customers feel safe. They know products are solid.
: Good standards make customers feel safe. They know products are solid. Fewer Problems : Quality checks mean fewer broken products. This saves cash on fixes.
: Quality checks mean fewer broken products. This saves cash on fixes. Sells Worldwide : Rules like ISO let companies sell everywhere. They show you're legit.
: Rules like ISO let companies sell everywhere. They show you're legit. Looks Green : Rules like ASTM D6868 show you care about the planet. This pulls in eco-friendly buyers.
: Rules like ASTM D6868 show you care about the planet. This pulls in eco-friendly buyers. Avoids Trouble: Following FDA or REACH keeps companies out of legal messes.
Rules are great but can be hard to follow. Here's the tricky stuff:
Testing and approvals can cost a lot. Small companies might find lab fees or new gear tough. For example, ISO 9001 approval can cost $10,000 or more.
Rules are different in each country. A product okay for the FDA might need changes for REACH in Europe. This takes time and smarts.
Rules keep changing. For example, the EU banned single-use plastics in 2021. Companies gotta stay updated to avoid problems.
Here's how a plastic product company or plastic manufacturing company can keep quality high: Pick Safe Stuff: Use FDA-approved plastics like PET or HDPE for food and medical products. Test Everything: Work with labs like SGS to check strength and safety. Train Workers: Teach staff about rules like ISO 9001 to keep quality up. Watch Rules: Stay on top of FDA, REACH, and other rules with industry news. Be Green: Try biodegradable plastics like PLA to meet eco-goals.
Rules keep products safe, reliable, and good quality. They protect people and help sell globally.
PET and HDPE are safe for food. They're FDA-approved and don't leak chemicals into food.
They use recyclable or biodegradable plastics. They also join recycling programs and follow laws like REACH.
Bad quality can cause recalls, fines, or health risks. For example, bad medical plastics could hurt people and ruin a company's name.
Quality rules for plastics are getting tougher. By 2030, the EU wants all packaging to be recyclable or reusable. The market for green plastics is growing 15% a year. Companies are spending on better tests and eco-materials. For example, new tech like near-infrared sorting makes recycling easier. Tougher Rules : Laws like the EU's will push for greener plastics.
: Laws like the EU's will push for greener plastics. Better Tests : New tools will check chemicals faster and cheaper.
: New tools will check chemicals faster and cheaper. More Green Plastics : PLA and other eco-stuff will grow.
: PLA and other eco-stuff will grow. Global Rules: ISO and ASTM will line up more to make trade easy.
Quality rules keep plastic products safe, solid, and eco-friendly. Standards like ISO 9001, FDA, and REACH make sure they work great for food, medical, and other industries. Sure, costs and changing rules are tough, but following them builds trust and opens markets. A plastic product company or plastic manufacturing company can do great by picking safe materials, testing well, and staying updated. Start focusing on quality rules now to stay trusted and ahead.
TIME BUSINESS NEWS

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Politico
3 hours ago
- Politico
Senate passes first funding package ahead of shutdown cliff
'It's taken a great deal of work, good faith and negotiation to get to this point,' Senate Appropriations Chair Susan Collins (R-Maine). 'Congress has a responsibility, a constitutional responsibility under Article I, for the power of the purse. We are executing that responsibility.' The package would provide almost $154 billion for military construction and veterans programs. It would send more than $27 billion to the Agriculture department and FDA. Both represent a roughly 2 percent boost over current levels. The Senate rejected an amendment from Sen. Jeff Merkley, an appropriator and the top Democrat on the Senate Budget Committee, that would bar the rescission, or clawback, of funds in the bill by the White House. Democrats are worried that the administration will send another rescissions package ahead of the fall funding deadline, which would likely implode any hopes of getting a larger funding deal. Still, Sen. Patty Murray, the top Democrat on the Appropriations Committee, defended the smaller deal reached among senators, saying that the package 'rejects damaging cuts from Trump and House Republicans.' The Senate adopted by voice vote an amendment from Democratic Sens. Richard Blumenthal of Connecticut and Alex Padilla of California that would bar the use of any funds in the bill to reduce services provided by the Veterans Crisis Line. Senators rejected other amendments from Democrats including one that would have halted funding of the Agriculture Department reorganization and another to require a report on staffing reductions at the VA. They also rejected amendments from Sens. John Kennedy (R-La.) and Rick Scott (R-Fla.) that would have made deeper cuts to the Agriculture-FDA bill. The chamber also voted 75-21 to reject a proposal from Sen. Ron Johnson of Wisconsin that would bar lawmakers from taking credit for earmarks. It would require the funding to be revoked if a lawmaker were to ever tout their earmarks in interviews, mailings, speeches or even on the campaign trail.
Yahoo
5 hours ago
- Yahoo
Regeneron cancer bispecific rejected again; Allogene discloses trial death
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Regeneron Pharmaceuticals and Allogene Therapeutics, as well as updates from Bristol Myers Squibb, Biogen, and Argenx that you may have missed. Regeneron said two more of its new drugs hit regulatory setbacks because of Food and Drug Administration inspection issues at a third-party manufacturing plant. The company received a complete response letter for its bispecific cancer antibody odronextamab in lymphoma on July 30, due to issues at an Indiana factory that Novo Nordisk recently acquired from Catalent. In addition, the FDA will delay a decision on an application for high-dose Eylea processed at that plant. The odronextamab setback will require Regeneron to refile its application. The FDA previously rejected another Regeneron bispecific antibody, now approved as Lynozyfic, in multiple myeloma because of third-party manufacturing issues. — Jonathan Gardner Allogene Therapeutics is stopping use of an experimental immunosuppresive antibody called ALLO-647 following the death of a study participant, the company said Friday. ALLO-647 is part of a regimen meant to prepare patients for treatment with Allogene's donor-derived cell therapy for blood cancer, . But the antibody has been associated in rare cases with severe viral infections and, in this instance, was deemed related to an adenovirus infection that triggered liver failure in a participant in Allogene's pivotal trial. Allogene has closed the study arm with ALLO-647 and won't use it in future trials. It will move forward with a standard two-drug immunosuppressive regimen often used in cancer cell therapy. Results from the pivotal trial are still expected next year, the company said. — Ben Fidler Bristol Myers Squibb boosted its revenue outlook for 2025 by $700 million, driven by higher-than-expected sales of its off-patent cancer drug Revlimid. The company now expects full-year sales to be between $46.5 and $47.5 billion, although that may not flow through to the bottom line because of the $1.5 billion it has spent this year to license a BioNTech cancer drug. The unexpectedly high $838 million in Revlimid sales in the second quarter were part of a broader overperformance by the company, which beat Wall Street consensus for both its old and new drug business lines. Sales of Eliquis, Opdivo and Reblozyl were higher than expected, although cell therapy Abecma and new psoriasis drug Sotyktu were below, according to Leerink Partners analyst David Risinger. — Jonathan Gardner Biogen shares rose as much as 7% Thursday after the biotechnology company's latest earnings report surpassed Wall Street expectations. The company recorded $2.6 billion in revenue from April through the end of June, with $160 million coming from Leqembi, its closely watched drug for Alzheimer's disease. Biogen also raised its forecasts for 2025 revenue and earnings per share. To Brian Abrahams, an analyst at the investment bank RBC Capital Markets, the results were indicative that Biogen's efforts to turn around the business are starting to show. 'We see considerable room for upside,' he wrote in a note to clients. — Jacob Bell Shares of Argenx climbed by double digits following quarterly sales numbers for its autoimmune drug Vyvgart that handily topped investor expectations. According to Argenx, the company's multiple Vyvgart formulations combined to generate nearly $949 million in revenue between April and June, beating consensus estimates by more than $80 million. The 'blowout' performance included 'impressive' numbers across Vyvgart's approved indications and different versions, wrote William Blair analyst Myles Minter on Thursday. Leerink Partners' Thomas Smith now projects more than $9 billion in combined peak yearly sales. Argenx's market value rose past $40 billion on the news. — Ben Fidler Recommended Reading Eli Lilly's Julie Gilmore on finding up-and-coming companies and backing small biotechs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Miami Herald
9 hours ago
- Miami Herald
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Cash burn of $3.8 million in Q2 remains in line with projected quarterly range - Cash and investments are sufficient to fund operations through Q3'2026 at current cash burn rate - Commercial readiness activities underway for a phased launch of VenoValve® subject to FDA decision expected in 2H'2025 - IDE submission for enVVe® on track for 2H'2025 IRVINE, CA / ACCESS Newswire / August 1, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the second quarter 2025. "As the recent headlines around CVI confirmed, CVI is a pervasive and a progressive disease that is especially debilitating once it becomes severe. Our participation in several of the recent national news stories about CVI fits with our strategy of establishing enVVeno Medical as the world-wide leader in treatments for severe, deep venous disease. With several value driving milestones on the horizon, including FDA decisions on potential approval for the VenoValve and the pivotal study for enVVe, we continue to make strong progress in our mission to bring first-in-category, effective treatments to patients with severe CVI, and are well positioned to lead the ongoing national dialogue about CVI as further events are reported," commented Robert Berman, CEO of enVVeno Medical. Summary of Financial Results for the Second Quarter 2025The Company ended the quarter with $35.1 million in cash and investments. Based on management's current expectations, this capital has the potential to fund the Company through the third quarter of 2026, including pre-commercialization activities for the VenoValve, and the commencement of the enVVe pivotal study. Cash burn for the quarter was $3.8 million, consistent with the Company's projected cash burn rate of approximately $4-5 million per quarter. The Company anticipates that its cash burn rate will increase from current levels once commercialization of the VenoValve begins. The Company reported net losses of $6.7 million and $5.0 million for the three months ended June 30, 2025 and 2024, respectively, representing an increase in net loss of $1.7 million, or 35%. This increase was primarily due to higher operating expenses of $1.6 million resulting from additional personnel costs, the issuance of option grants, and non-recurring reserve and severance expenses, as well as a decrease in other income of $0.1 million. Clinical Program ProgressVenoValve®: Novel, First-In-Class Surgical Replacement Venous Valve Amended VenoValve PMA application in response to formal questions from U.S. Food and Drug Administration (FDA)Continue to respond to FDA questions and inquiries as they arisePresented positive interm, two-year data at Society for Vascular Surgery (SVS) 2025 Vascular Annual MeetingPMA decision from FDA expected 2H'2025 enVVe®: Novel, First-In-Class Non-Surgical Transcatheter-Based Replacement Venous Valve Successfully completed final wave for the shorter-term subjects in 6-month pre-clinical GLP studyAwaiting final pathology form the GLP studySuccessfully completed other testing necessary for IDE filingIDE filing for enVVe pivotal trial on track for 2H'2025 President Trump CVI DiagnosisFollowing President Trump's recent diagnosis of what appears to be moderate CVI, Dr. Marc Glickman, Senior Vice President and Chief Medical Officer of enVVeno Medical was featured in several national television news segments, podcasts, radio reports, and news articles, including Fox News, NewsMax, Morning Wire, and the N.Y. Post. To view this media, click here. About enVVeno Medical CorporationenVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking StatementsThis press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. ### INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation